|
Koichiro Yano
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Associate Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. |
| Journal | Formal name：Modern rheumatology Abbreviation：Mod Rheumatol ISSN code：14397609/14397595 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 29(3),pp.413-417 |
| Author and coauthor | Mochizuki Takeshi†, Ikari Katsunori, Yano Koichiro, Sato Motoaki, Okazaki Ken |
| Publication date | 2019/05 |
| Summary | OBJECTIVE:To examine the deterioration of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with abatacept over the long-term.METHODS:We examined 131 patients with RA who had been treated with abatacept for more than 1 year. All patients underwent high-resolution computed tomographic (HRCT) scanning of the chest before administration of abatacept, and we examined deterioration of ILD over a follow-up period after administration of abatacept was initiated.RESULTS:Eleven patients (8.4%) showed deterioration of ILD over a mean follow-up period of 47.8 months. The factors related to ILD deterioration were use of methotrexate (MTX) [odds ratio 12.75, 95% confidence interval (CI) 1.09-148.77], and change in Krebs von-den Lungen-6 (odds ratio 1.00, 95% CI 1.00-1.01), according to multivariate logistic regression analysis.CONCLUSION:MTX in patients with RA treated with abatacept was a risk factor for deterioration of ILD. Discontinuation of MTX should be considered one of treatment reduction to prevent the deterioration of ILD. |
| DOI | 10.1080/14397595.2018.1481566 |
| PMID | 29798700 |